July 16, 2013

Johnson & Johnson Reports 2013 Second-Quarter Results:

Sales of $17.9 Billion increased 8.5% Versus 2012 Second Quarter;
Second-Quarter EPS was $1.33
Excluding Special Items, 2013 Second-Quarter EPS of $1.48 Increased 13.8%*

NEW BRUNSWICK, N.J., July 16, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $17.9 billion for the second quarter of 2013, an increase of 8.5% as compared to the second quarter of 2012. Operational results increased 10.0% and the negative impact of currency was 1.5%. Domestic sales increased 8.0%. International sales increased 9.0%, reflecting operational growth of 11.8% and a negative currency impact of 2.8%. Sales included the impact of the acquisition of Synthes, Inc., net of the divestiture of the DePuy trauma business. Excluding this impact, worldwide operational sales growth was 5.6%.

Net earnings and diluted earnings per share for the second quarter of 2013 were $3.8 billion and $1.33, respectively. The second quarter results included the gain on the sale of the equity interest owned in Elan Corporation, plc, as previously disclosed. Second quarter 2013 net earnings included after-tax special items of approximately $0.5 billion, related to litigation expenses, integration and transaction costs associated with the acquisition of Synthes, Inc, and program costs associated with the DePuy ASRTM Hip. Second quarter 2012 net earnings included after-tax special items of approximately $2.2 billion as shown in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items, net earnings for the current quarter were $4.3 billion and diluted earnings per share were $1.48, representing increases of 17.7% and 13.8%, respectively, as compared to the same period in 2012.*

"Our strong second-quarter results reflect the progress we've made against our near-term priorities of delivering on our financial commitments, restoring a reliable supply of over-the-counter products to consumers, continuing the successful integration of Synthes and building on the momentum in our pharmaceutical business," said Alex Gorsky, Chairman and Chief Executive Officer. "Our talented colleagues at Johnson & Johnson continue to bring meaningful innovations to patients and consumers around the world and have positioned us well to deliver sustainable growth."

The Company increased its earnings guidance for full-year 2013 to $5.40 - $5.47 per share. The Company's guidance excludes the impact of special items.

Worldwide Consumer sales of $3.7 billion for the second quarter represented an increase of 1.1% versus the prior year consisting of an operational increase of 1.7% and a negative impact from currency of 0.6%. Domestic sales increased 1.0%. International sales increased 1.1%, which reflected an operational increase of 2.0% and a negative currency impact of 0.9%.

Positive contributors to operational results were upper respiratory over-the-counter medicines; TYLENOL® and MOTRIN® analgesics; international sales of LISTERINE® mouthwash; baby care products and women's sanitary protection products.

Worldwide Pharmaceutical sales of $7.0 billion for the second quarter represented an increase of 11.7% versus the prior year with operational growth of 12.9% and a negative impact from currency of 1.2%. Domestic sales increased 9.1%. International sales increased 14.1% which reflected an operational increase of 16.5% and a negative currency impact of 2.4%.

Primary contributors to operational sales growth were REMICADE® (infliximab) and SIMPONI® (golimumab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases; STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the acute and maintenance treatment of schizophrenia in adults; VELCADE® (bortezomib), a treatment for multiple myeloma; PREZISTA® (darunavir), a treatment for HIV; and sales of recently launched products.

The strong sales results of recently launched products included ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; XARELTO® (rivaroxaban), an oral anticoagulant; and INCIVO® (telaprevir), a direct acting antiviral protease inhibitor, for the treatment of genotype-1 chronic hepatitis C virus.

During the quarter, the U.S. Food and Drug Administration (FDA) approved SIMPONI® (golimumab) for the treatment of moderately to severely active ulcerative colitis in adult patients who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine.

Additionally, the FDA granted Breakthrough Therapy Designation for daratumumab for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and IMiD. Daratumumab is an investigational human CD38 monoclonal antibody licensed from Genmab A/S.

In addition, a New Drug Application was submitted to the FDA under Breakthrough Therapy Designation for the use of ibrutinib in previously treated patients with chronic lymphocytic leukemia /small lymphocytic lymphoma, and for use in previously treated patients with mantle cell lymphoma.

Also during the quarter, a Marketing Authorization Application was submitted to the European Medicines Agency seeking approval for simeprevir (TMC435). Simeprevir is a new generation NS3/4A protease inhibitor, administered as one 150mg capsule once daily in combination with peginterferon alfa and ribavirin, indicated for the treatment of genotype 1 or genotype 4 chronic hepatitis C in adult patients with compensated liver disease (including cirrhosis), with or without HIV-1 co-infection, who are treatment naive or who have failed previous interferon therapy (pegylated or non-pegylated) with or without ribavirin.

The Committee for Medical Products for Human Use of The European Medicines Agency granted a positive opinion on two variations relating to the use of VELCADE® (bortezomib). The first recommendation was for the use of VELCADE® as retreatment in adult patients who have previously responded to treatment with the same medicine. The second recommendation was as induction therapy in combination with dexamethasone or dexamethasone and thalidomide for adult patients with previously untreated multiple myeloma that are eligible for high-dose chemotherapy with haematological stem cell transplantation. In addition, the European Commission approved a new twice daily (BID) dosing of INCIVO® (telaprevir), a direct acting antiviral protease inhibitor, in combination with pegylated-interferon and ribavirin for naive and previous treatment experienced patients.

A definitive agreement was signed in June to acquire Aragon Pharmaceuticals, Inc., a privately-held, pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers. The acquisition includes Aragon's androgen receptor antagonist program. Aragon's lead product candidate is a second generation androgen receptor signaling inhibitor, ARN-509, in Phase 2 development for castration resistant prostate cancer.

Worldwide Medical Devices and Diagnostics sales of $7.2 billion for the second quarter represented an increase of 9.6% versus the prior year consisting of an operational increase of 12.0% and a negative currency impact of 2.4%. Domestic sales increased 9.8%. International sales increased 9.4%, which reflected an operational increase of 13.7% and a negative currency impact of 4.3%. Sales included the impact of the acquisition of Synthes, Inc., net of the divestiture of the DePuy trauma business. Excluding this impact, worldwide operational sales growth was 0.5%.

Primary contributors to operational growth were sales from the acquisition of Synthes, Inc., in the Orthopaedics business; Biosense Webster's electrophysiology products in the Cardiovascular Care business; Vision Care's 1-Day ACUVUE® TRUEYE and 1-Day ACUVUE® MOIST® disposable contact lenses; and biosurgical and international sales of energy products in the Specialty Surgery business.

During the quarter, the FDA granted Premarket Approval for the SEDASYS® System, the first computer-assisted personalized sedation system for healthy patients undergoing sedation during routine colonoscopy and esophagogastroduodenoscopy procedures.

About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 275 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings and diluted earnings per share excluding special items are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the financial schedules accompanying this press release and can be found in the Investor Relations section of the Company's website at www.investor.jnj.com.

Johnson & Johnson will conduct a conference call with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliation of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development can be found on the Company's website at www.jnj.com.

NOTE TO INVESTORS

(This release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation or government action; impact of business combinations; financial distress and bankruptcies experienced by significant customers and suppliers; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays; complex global supply chains with increasing regulatory requirements; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

 



Johnson & Johnson and Subsidiaries

                                     

Supplementary Sales Data

                                     
                                       

(Unaudited; Dollars in Millions)

SECOND QUARTER

 

SIX MONTHS

         

Percent
Change

           

Percent
Change

 

2013

 

2012

 

Total

 

Operations

 

Currency

 

2013

 

2012

 

Total

 

Operations

 

Currency

Sales to customers by

                                     

segment of business

                       

 
           
                                       

Consumer

                                     

U.S.

$ 1,326

 

1,313

 

1.0

%

1.0

 

-

 

$ 2,674

 

2,629

 

1.7

%

1.7

 

-

International

2,332

 

2,306

 

1.1

 

2.0

 

(0.9)

 

4,659

 

4,585

 

1.6

 

2.9

 

(1.3)

 

3,658

 

3,619

 

1.1

 

1.7

 

(0.6)

 

7,333

 

7,214

 

1.6

 

2.4

 

(0.8)

                                       

Pharmaceutical

                                     

U.S.

3,377

 

3,094

 

9.1

 

9.1

 

-

 

6,848

 

6,120

 

11.9

 

11.9

 

-

International

3,648

 

3,197

 

14.1

 

16.5

 

(2.4)

 

6,945

 

6,304

 

10.2

 

12.4

 

(2.2)

 

7,025

 

6,291

 

11.7

 

12.9

 

(1.2)

 

13,793

 

12,424

 

11.0

 

12.1

 

(1.1)

                                       

Med Devices & Diagnostics

                                     

U.S.

3,243

 

2,953

 

9.8

 

9.8

 

-

 

6,449

 

5,830

 

10.6

 

10.6

 

-

International

3,951

 

3,612

 

9.4

 

13.7

 

(4.3)

 

7,807

 

7,146

 

9.2

 

12.9

 

(3.7)

 

7,194

 

6,565

 

9.6

 

12.0

 

(2.4)

 

14,256

 

12,976

 

9.9

 

12.0

 

(2.1)

                                       

U.S.

7,946

 

7,360

 

8.0

 

8.0

 

-

 

15,971

 

14,579

 

9.5

 

9.5

 

-

International

9,931

 

9,115

 

9.0

 

11.8

 

(2.8)

 

19,411

 

18,035

 

7.6

 

10.2

 

(2.6)

Worldwide

$17,877

 

16,475

 

8.5

%

10.0

 

(1.5)

 

$35,382

 

32,614

 

8.5

%

9.9

 

(1.4)

 

 

Johnson & Johnson and Subsidiaries

                                     

Supplementary Sales Data

                                     
                                       

(Unaudited; Dollars in Millions)

SECOND QUARTER

 

SIX MONTHS

             

Percent Change

                 

Percent Change

   
 

2013

 

2012

 

Total

 

Operations

 

Currency

 

2013

 

2012

 

Total

 

Operations

 

Currency

Sales to customers by

                                     

geographic area

                                     
                                       

U.S.

$ 7,946

 

7,360

 

8.0

%

8.0

 

-

 

$15,971

 

14,579

 

9.5

%

9.5

 

-

                                       

Europe

4,672

 

4,165

 

12.2

 

11.4

 

0.8

 

9,153

 

8,359

 

9.5

 

8.8

 

0.7

Western Hemisphere excluding U.S.

1,905

 

1,728

 

10.2

 

14.0

 

(3.8)

 

3,688

 

3,442

 

7.1

 

11.5

 

(4.4)

Asia-Pacific, Africa

3,354

 

3,222

 

4.1

 

11.0

 

(6.9)

 

6,570

 

6,234

 

5.4

 

11.4

 

(6.0)

International

9,931

 

9,115

 

9.0

 

11.8

 

(2.8)

 

19,411

 

18,035

 

7.6

 

10.2

 

(2.6)

                                       

Worldwide

$17,877

 

$16,475

 

8.5

%

10.0

 

(1.5)

 

$35,382

 

$32,614

 

8.5

%

9.9

 

(1.4)

 



Johnson & Johnson and Subsidiaries

                 

Condensed Consolidated Statement of Earnings

                 
                   

(Unaudited; in Millions Except Per Share Figures)

SECOND QUARTER

                   
 

2013

 

2012

 

Percent

     

Percent

     

Percent

 

Increase

 

Amount

 

to Sales

 

Amount

 

to Sales

 

(Decrease)

Sales to customers

$ 17,877

 

100.0

 

$ 16,475

 

100.0

 

8.5

Cost of products sold

5,489

 

30.7

 

5,143

 

31.2

 

6.7

Selling, marketing and administrative expenses

5,376

 

30.1

 

4,965

 

30.1

 

8.3

Research and development expense

1,946

 

10.9

 

1,766

 

10.7

 

10.2

In-process research and development

-

 

-

 

429

 

2.6

   

Interest (income) expense, net

101

 

0.6

 

129

 

0.8

   

Other (income) expense, net

172

 

0.9

 

2,008

 

12.2

   

Earnings before provision for taxes on income

4,793

 

26.8

 

2,035

 

12.4

 

135.5

Provision for taxes on income

960

 

5.4

 

627

 

3.9

 

53.1

Net earnings

$ 3,833

 

21.4

 

$ 1,408

 

8.5

 

172.2

                   

Net earnings per share (Diluted)

$ 1.33

     

$ 0.50

     

166.0

                   

Average shares outstanding (Diluted)

2,893.0

     

2,798.2

       
                   

Effective tax rate

20.0

%

   

30.8

%

     
                   

Adjusted earnings before provision for taxes and net earnings (1)

             

Earnings before provision for taxes on income

$ 5,359

 

30.0

 

$ 4,646

 

28.2

 

15.3

Net earnings

$ 4,289

 

24.0

 

$ 3,644

 

22.1

 

17.7

Net earnings per share (Diluted)

$ 1.48

     

$ 1.30

     

13.8

Effective tax rate

20.0

%

   

21.6

%

     
                   

(1) See Reconciliation of Non-GAAP Financial Measures.

                 

 



Johnson & Johnson and Subsidiaries

                 

Condensed Consolidated Statement of Earnings

                 
                   

(Unaudited; in Millions Except Per Share Figures)

SIX MONTHS

                   
 

2013

 

2012

 

Percent

     

Percent

     

Percent

 

Increase

 

Amount

 

to Sales

 

Amount

 

to Sales

 

(Decrease)

Sales to customers

$ 35,382

 

100.0

 

$ 32,614

 

100.0

 

8.5

Cost of products sold

11,043

 

31.2

 

10,058

 

30.8

 

9.8

Selling, marketing and administrative expenses

10,599

 

30.0

 

9,980

 

30.6

 

6.2

Research and development expense

3,730

 

10.5

 

3,411

 

10.5

 

9.4

In-process research and development

64

 

0.2

 

429

 

1.3

   

Interest (income) expense, net

205

 

0.6

 

259

 

0.8

   

Other (income) expense, net

687

 

1.9

 

1,397

 

4.3

   

Earnings before provision for taxes on income

9,054

 

25.6

 

7,080

 

21.7

 

27.9

Provision for taxes on income

1,724

 

4.9

 

1,762

 

5.4

 

(2.2)

Net earnings

$ 7,330

 

20.7

 

$ 5,318

 

16.3

 

37.8

                   

Net earnings per share (Diluted)

$ 2.55

     

$ 1.91

     

33.5

                   

Average shares outstanding (Diluted)

2,878.8

     

2,792.4

       
                   

Effective tax rate

19.0

%

   

24.9

%

     
                   

Adjusted earnings before provision for taxes and net earnings (1)

             

Earnings before provision for taxes on income

$ 10,429

 

29.5

 

$ 9,574

 

29.4

 

8.9

Net earnings

$ 8,396

 

23.7

 

$ 7,448

 

22.8

 

12.7

Net earnings per share (Diluted)

$ 2.92

     

$ 2.67

     

9.4

Effective tax rate

19.5

%

   

22.2

%

     
                   

(1) See Reconciliation of Non-GAAP Financial Measures.

                 

 

Johnson & Johnson and Subsidiaries

                         

Reconciliation of Non-GAAP Financial Measures

                         
                           
 

Second Quarter

 

% Incr. /

   

Six Months YTD

 

% Incr. /

 

(Dollars in Millions Except Per Share Data)

2013

 

2012

 

(Decr.)

   

2013

 

2012

 

(Decr.)

 
                           

Earnings before provision for taxes on income - as reported

$ 4,793

 

2,035

 

135.5

%

 

$ 9,054

 

$ 7,080

 

27.9

%

                           

Intangible asset write-downs

-

 

939

       

-

 

939

     
                           

Litigation expenses

375

 

669

       

904

 

669

     
                           

Synthes integration/transaction costs and currency related

122

 

574

       

380

 

457

     
                           

In-process research and development

-

 

429

       

64

 

429

     
                           

DePuy ASR™Hip program

69

 

-

       

82

 

-

     
                           

Other

-

 

-

       

(55)

 

-

     
                           

Earnings before provision for taxes on income - as adjusted

$ 5,359

 

4,646

 

15.3

%

 

$ 10,429

 

9,574

 

8.9

%

                           

Net Earnings - as reported

$ 3,833

 

1,408

 

172.2

%

 

$ 7,330

 

5,318

 

37.8

%

                           

Intangible asset write-downs

-

 

717

       

-

 

717

     
                           

Litigation expenses

308

 



611

       

699

 

611

     
                           

Synthes integration/transaction costs and currency related

87

 

564

       

270

 

458

     
                           

In-process research and development

-

 

344

       

42

 

344

     
                           

DePuy ASR™Hip program

61

 

-

       

91

 

-

     
                           

Other

-

 

-

       

(36)

 

-

     
                           

Net Earnings - as adjusted

$ 4,289

 

3,644

 

17.7

%

 

$ 8,396

 

7,448

 

12.7

%

                           

Diluted Net Earnings per share - as reported

$ 1.33

 

0.50

 

166.0

%

 

$ 2.55

 

1.91

 

33.5

%

                           

Intangible asset write-downs

-

 

0.26

       

-

 

0.26

     
                           

Litigation expenses

0.10

 

0.22

       

0.24

 

0.22

     
                           

Synthes integration/transaction costs and currency related

0.03

 

0.20

       

0.09

 

0.16

     
                           

In-process research and development

-

 

0.12

       

0.02

 

0.12

     
                           

DePuy ASR™Hip program

0.02

 

-

       

0.03

 

-

     
                           

Other

-

 

-

       

(0.01)

 

-

     
                           

Diluted Net Earnings per share - as adjusted

$ 1.48

 

1.30

 

13.8

%

 

$ 2.92

 

2.67

 

9.4

%

                           
                           

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes

   

on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.

         

 

 

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

 

SECOND QUARTER

 

SIX MONTHS

         

% Change

         

% Change

   

2013

 

2012

Reported

Operational (1)

Currency

   

2013

 

2012

Reported

Operational (1)

Currency

CONSUMER SEGMENT (2) (4)

                             

BABY CARE

                             

US

 

$ 106

 

106

0.0%

0.0%

-

   

$ 209

 

205

2.0%

2.0%

-

Intl

 

480

 

472

1.7%

3.8%

-2.1%

   

941

 

913

3.1%

5.7%

-2.6%

WW

 

586

 

578

1.4%

3.1%

-1.7%

   

1,150

 

1,118

2.9%

5.0%

-2.1%

ORAL CARE

                             

US

 

149

 

159

-6.3%

-6.3%

-

   

307

 

314

-2.2%

-2.2%

-

Intl

 

257

 

249

3.2%

4.3%

-1.1%

   

502

 

481

4.4%

5.8%

-1.4%

WW

 

406

 

408

-0.5%

0.2%

-0.7%

   

809

 

795

1.8%

2.6%

-0.8%

OTC (3)

                             

US

 

290

 

247

17.4%

17.4%

-

   

644

 

538

19.7%

19.7%

-

Intl

 

641

 

636

0.8%

0.9%

-0.1%

   

1,330

 

1,296

2.6%

3.0%

-0.4%

WW

 

931

 

883

5.4%

5.4%

0.0%

   

1,974

 

1,834

7.6%

7.9%

-0.3%

SKIN CARE

                             

US

 

463

 

471

-1.7%

-1.7%

-

   

916

 

924

-0.9%

-0.9%

-

Intl

 

445

 

442

0.7%

1.0%

-0.3%

   

894

 

896

-0.2%

0.3%

-0.5%

WW

 

908

 

913

-0.5%

-0.4%

-0.1%

   

1,810

 

1,820

-0.5%

-0.3%

-0.2%

WOMEN'S HEALTH

                             

US

 

84

 

80

5.0%

5.0%

-

   

165

 

173

-4.6%

-4.6%

-

Intl

 

327

 

322

1.6%

3.4%

-1.8%

   

647

 

638

1.4%

4.1%

-2.7%

WW

 

411

 

402

2.2%

3.6%

-1.4%

   

812

 

811

0.1%

2.2%

-2.1%

WOUND CARE/OTHER (3)

                             

US

 

234

 

250

-6.4%

-6.4%

-

   

433

 

475

-8.8%

-8.8%

-

Intl

 

182

 

185

-1.6%

-1.4%

-0.2%

   

345

 

361

-4.4%

-4.0%

-0.4%

WW

 

416

 

435

-4.4%

-4.3%

-0.1%

   

778

 

836

-6.9%

-6.7%

-0.2%

                               

TOTAL CONSUMER

                             

US

 

1,326

 

1,313

1.0%

1.0%

-

   

2,674

 

2,629

1.7%

1.7%

-

Intl

 

2,332

 

2,306

1.1%

2.0%

-0.9%

   

4,659

 

4,585

1.6%

2.9%

-1.3%

WW

 

$ 3,658

 

3,619

1.1%

1.7%

-0.6%

   

$ 7,333

 

7,214

1.6%

2.4%

-0.8%

                               
                               

See footnotes at end of schedule

                             

 

 

 

                     
                     

Supplemental Sales Information

                   
 

2012

   

2013

   

Q1

 

Q2

Q3

Q4

FY

   

Q1

OTC

                   

US

 

291

 

247

263

273

1,074

   

354

Intl

 

660

 

636

653

743

2,692

   

689

WW

 

951

 

883

916

1,016

3,766

   

1,043

                     

WOUND CARE/OTHER

                   

US

 

225

 

250

214

195

884

   

199

Intl

 

176

 

185

163

152

676

   

163

WW

 

401

 

435

377

347

1,560

   

362

 

 

 

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

 

SECOND QUARTER

 

SIX MONTHS

         

% Change

         

% Change

   

2013

 

2012

Reported

Operational (1)

Currency

   

2013

 

2012

Reported

Operational (1)

Currency

PHARMACEUTICAL SEGMENT (2) (4)

                             

IMMUNOLOGY

                             

US

 

$ 1,578

 

1,471

7.3%

7.3%

-

   

$ 3,217

 

2,924

10.0%

10.0%

-

Intl

 

663

 

448

48.0%

51.5%

-3.5%

   

1,228

 

890

38.0%

40.9%

-2.9%

WW

 

2,241

 

1,919

16.8%

17.6%

-0.8%

   

4,445

 

3,814

16.5%

17.2%

-0.7%

REMICADE

                             

US

 

926

 

890

4.0%

4.0%

-

   

1,896

 

1,772

7.0%

7.0%

-

US Exports (5)

 

332

 

366

-9.3%

-9.3%

-

   

681

 

744

-8.5%

-8.5%

-

Intl

 

414

 

267

55.1%

58.2%

-3.1%

   

695

 

28

31.6%

34.0%

-2.4%

WW

 

1,672

 

1,523

9.8%

10.3%

-0.5%

   

3,272

 

3,044

7.5%

7.9%

-0.4%

SIMPONI

                             

US

 

87

 

63

38.1%

38.1%

-

   

181

 

127

42.5%

42.5%

-

Intl

 

88

 

62

41.9%

48.3%

-6.4%

   

231

 

114

*

*

-4.5%

WW

 

175

 

125

40.0%

43.2%

-3.2%

   

412

 

241

71.0%

73.5%

-2.5%

STELARA

                             

US

 

233

 

152

53.3%

53.3%

-

   

459

 

281

63.3%

63.3%

-

Intl

 

138

 

96

43.8%

45.4%

-1.6%

   

258

 

188

37.2%

38.4%

-1.2%

WW

 

371

 

248

49.6%

50.2%

-0.6%

   

717

 

469

52.9%

53.4%

-0.5%

OTHER IMMUNOLOGY

                             

US

 

-

 

-

-

-

-

   

-

 

-

-

-

-

Intl

 

23

 

23

0.0%

1.1%

-1.1%

   

44

 

60

-26.7%

-26.1%

-0.6%

WW

 

23

 

23

0.0%

1.1%

-1.1%

   

44

 

60

-26.7%

-26.1%

-0.6%

INFECTIOUS DISEASES

                             

US

 

259

 

237

9.3%

9.3%

-

   

497

 

479

3.8%

3.8%

-

Intl

 

711

 

551

29.0%

30.2%

-1.2%

   

1,288

 

1,064

21.1%

22.2%

-1.1%

WW

 

970

 

788

23.1%

23.9%

-0.8%

   

1,785

 

1,543

15.7%

16.5%

-0.8%

INCIVO

                             

US

 

-

 

-

-

-

-

   

-

 

-

-

-

-

Intl

 

172

 

102

68.6%

71.8%

-3.2%

   

334

 

234

42.7%

45.4%

-2.7%

WW

 

172

 

102

68.6%

71.8%

-3.2%

   

334

 

234

42.7%

45.4%

-2.7%

INTELENCE

                             

US

 

44

 

42

4.8%

4.8%

-

   

91

 

85

7.1%

7.1%

-

Intl

 

59

 

49

20.4%

21.0%

-0.6%

   

101

 

86

17.4%

18.0%

-0.6%

WW

 

103

 

91

13.2%

13.5%

-0.3%

   

192

 

171

12.3%

12.6%

-0.3%

PREZISTA

                             

US

 

196

 

166

18.1%

18.1%

-

   

363

 

326

11.3%

11.3%

-

Intl

 

239

 

207

15.5%

16.0%

-0.5%

   

439

 

371

18.3%

18.7%

-0.4%

WW

 

435

 

373

16.6%

16.9%

-0.3%

   

802

 

697

15.1%

15.3%

-0.2%

OTHER INFECTIOUS DISEASES

                             

US

 

19

 

29

-34.5%

-34.5%

-

   

43

 

68

-36.8%

-36.8%

-

Intl

 

241

 

193

24.9%

25.8%

-0.9%

   

414

 

373

11.0%

11.9%

-0.9%

WW

 

260

 

222

17.1%

17.9%

-0.8%

   

457

 

441

3.6%

4.3%

-0.7%

                               

 

 

 

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

 

SECOND QUARTER

 

SIX MONTHS

         

% Change

         

% Change

   

2013

 

2012

Reported

Operational (1)

Currency

   

2013

 

2012

Reported

Operational (1)

Currency

                               

NEUROSCIENCE

                             

US

 

626

 

658

-4.9%

-4.9%

-

   

1,372

 

1,332

3.0%

3.0%

-

Intl

 

1,054

 

1,056

-0.2%

3.8%

-4.0%

   

2,052

 

2,029

1.1%

4.6%

-3.5%

WW

 

1,680

 

1,714

-2.0%

0.4%

-2.4%

   

3,424

 

3,361

1.9%

4.0%

-2.1%

CONCERTA/METHYLPHENIDATE

                             

US

 

85

 

146

-41.8%

-41.8%

-

   

224

 

343

-34.7%

-34.7%

-

Intl

 

130

 

122

6.6%

8.9%

-2.3%

   

247

 

233

6.0%

7.9%

-1.9%

WW

 

215

 

268

-19.8%

-18.7%

-1.1%

   

471

 

576

-18.2%

-17.4%

-0.8%

INVEGA

                             

US

 

76

 

76

0.0%

0.0%

-

   

147

 

145

1.4%

1.4%

-

Intl

 

74

 

66

12.1%

18.3%

-6.2%

   

135

 

118

14.4%

19.9%

-5.5%

WW

 

150

 

142

5.6%

8.4%

-2.8%

   

282

 

263

7.2%

9.7%

-2.5%

INVEGA SUSTENNA/ XEPLION

                             

US

 

158

 

120

31.7%

31.7%

-

   

322

 

220

46.4%

46.4%

-

Intl

 

132

 

75

76.0%

75.0%

1.0%

   

252

 

136

85.3%

84.4%

0.9%

WW

 

290

 

195

48.7%

48.3%

0.4%

   

574

 

356

61.2%

60.9%

0.3%

RISPERDAL CONSTA

                             

US

 

107

 

110

-2.7%

-2.7%

-

   

213

 

223

-4.5%

-4.5%

-

Intl

 

229

 

245

-6.5%

-3.7%

-2.8%

   

458

 

493

-7.1%

-4.9%

-2.2%

WW

 

336

 

355

-5.4%

-3.5%

-1.9%

   

671

 

716

-6.3%

-4.8%

-1.5%

OTHER NEUROSCIENCE

                             

US

 

200

 

206

-2.9%

-2.9%

-

   

466

 

401

16.2%

16.2%

-

Intl

 

489

 

548

-10.8%

-5.5%

-5.3%

   

960

 

1,049

-8.5%

-3.7%

-4.8%

WW

 

689

 

754

-8.6%

-4.8%

-3.8%

   

1,426

 

1,450

-1.7%

1.8%

-3.5%

ONCOLOGY

                             

US

 

206

 

119

73.1%

73.1%

-

   

405

 

226

79.2%

79.2%

-

Intl

 

679

 

467

45.4%

48.1%

-2.7%

   

1,274

 

956

33.3%

35.8%

-2.5%

WW

 

885

 

586

51.0%

53.2%

-2.2%

   

1,679

 

1,182

42.0%

44.0%

-2.0%

VELCADE

                             

US

 

-

 

-

-

-

-

   

-

 

-

-

-

-

Intl

 

379

 

318

19.2%

22.7%

-3.5%

   

732

 

671

9.1%

12.1%

-3.0%

WW

 

379

 

318

19.2%

22.7%

-3.5%

   

732

 

671

9.1%

12.1%

-3.0%

ZYTIGA

                             

US

 

174

 

113

54.0%

54.0%

-

   

335

 

213

57.3%

57.3%

-

Intl

 

221

 

119

85.7%

85.2%

0.5%

   

404

 

219

84.5%

84.4%

0.1%

WW

 

395

 

232

70.3%

70.0%

0.3%

   

739

 

432

71.1%

71.1%

0.0%

OTHER ONCOLOGY

                             

US

 

32

 

6

*

*

-

   

70

 

13

*

*

-

Intl

 

79

 

30

*

*

-7.4%

   

138

 

66

*

*

-6.0%

WW

 

111

 

36

*

*

-6.1%

   

208

 

79

*

*

-5.0%

                               

 

 

 

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

 

SECOND QUARTER

 

SIX MONTHS

         

% Change

         

% Change

   

2013

 

2012

Reported

Operational (1)

Currency

   

2013

 

2012

Reported

Operational (1)

Currency

TOTAL OTHER

                             

US

 

708

 

609

16.3%

16.3%

-

   

1,357

 

1,159

17.1%

17.1%

-

Intl

 

541

 

675

-19.9%

-19.9%

0.0%

   

1,103

 

1,365

-19.2%

-18.6%

-0.6%

WW

 

1,249

 

1,284

-2.7%

-2.7%

0.0%

   

2,460

 

2,524

-2.5%

-2.2%

-0.3%

ACIPHEX/PARIET

                             

US

 

97

 

104

-6.7%

-6.7%

-

   

200

 

200

0.0%

0.0%

-

Intl

 

59

 

128

-53.9%

-54.0%

0.1%

   

108

 

254

-57.5%

-57.3%

-0.2%

WW

 

156

 

232

-32.8%

-32.8%

0.0%

   

308

 

454

-32.2%

-32.1%

-0.1%

PROCRIT/EPREX

                             

US

 

190

 

232

-18.1%

-18.1%

-

   

423

 

436

-3.0%

-3.0%

-

Intl

 

145

 

169

-14.2%

-14.6%

0.4%

   

290

 

341

-15.0%

-15.3%

0.3%

WW

 

335

 

401

-16.5%

-16.7%

0.2%

   

713

 

777

-8.2%

-8.3%

0.1%

XARELTO

                             

US

 

189

 

49

*

*

-

   

347

 

76

*

*

-

Intl

 

-

 

-

-

-

-

   

-

 

-

-

-

-

WW

 

189

 

49

*

*

-

   

347

 

76

*

*

-

OTHER

                             

US

 

232

 

224

3.6%

3.6%

-

   

387

 

447

-13.4%

-13.4%

-

Intl

 

337

 

378

-10.8%

-10.5%

-0.3%

   

705

 

770

-8.4%

-7.4%

-1.0%

WW

 

569

 

602

-5.5%

-5.3%

-0.2%

   

1,092

 

1,217

-10.3%

-9.7%

-0.6%

                               

TOTAL PHARMACEUTICAL

                             

US

 

3,377

 

3,094

9.1%

9.1%

-

   

6,848

 

6,120

11.9%

11.9%

-

Intl

 

3,648

 

3,197

14.1%

16.5%

-2.4%

   

6,945

 

6,304

10.2%

12.4%

-2.2%

WW

 

$ 7,025

 

6,291

11.7%

12.9%

-1.2%

   

$ 13,793

 

12,424

11.0%

12.1%

-1.1%

                               

 

 

 

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

 

SECOND QUARTER

 

SIX MONTHS

         

% Change

         

% Change

   

2013

 

2012

Reported

Operational (1)

Currency

   

2013

 

2012

Reported

Operational (1)

Currency

MEDICAL DEVICES AND DIAGNOSTICS (2)

                             

CARDIOVASCULAR CARE

                             

US

 

$ 204

 

195

4.6%

4.6%

-

   

$ 402

 

371

8.4%

8.4%

-

Intl

 

325

 

309

5.2%

9.6%

-4.4%

   

640

 

615

4.1%

8.0%

-3.9%

WW

 

529

 

504

5.0%

7.7%

-2.7%

   

1,042

 

986

5.7%

8.1%

-2.4%

DIABETES CARE

                             

US

 

259

 

337

-23.1%

-23.1%

-

   

542

 

689

-21.3%

-21.3%

-

Intl

 

330

 

336

-1.8%

-0.5%

-1.3%

   

647

 

654

-1.1%

0.2%

-1.3%

WW

 

589

 

673

-12.5%

-11.8%

-0.7%

   

1,189

 

1,343

-11.5%

-10.9%

-0.6%

DIAGNOSTICS

                             

US

 

241

 

258

-6.6%

-6.6%

-

   

489

 

511

-4.3%

-4.3%

-

Intl

 

242

 

256

-5.5%

-1.5%

-4.0%



   

471

 

515

-8.5%

-4.7%

-3.8%

WW

 

483

 

514

-6.0%

-4.0%

-2.0%

   

960

 

1,026

-6.4%

-4.5%

-1.9%

INFECTION PREVENTION/OTHER

                             

US

 

95

 

99

-4.0%

-4.0%

-

   

180

 

215

-16.3%

-16.3%

-

Intl

 

139

 

131

6.1%

12.3%

-6.2%

   

266

 

259

2.7%

8.2%

-5.5%

WW

 

234

 

230

1.7%

5.2%

-3.5%

   

446

 

474

-5.9%

-2.9%

-3.0%

ORTHOPAEDICS

                             

US

 

1,274

 

873

45.9%

45.9%

-

   

2,535

 

1,656

53.1%

53.1%

-

Intl

 

1,111

 

755

47.2%

52.4%

-5.2%

   

2,235

 

1,465

52.6%

56.3%

-3.7%

WW

 

2,385

 

1,628

46.5%

48.9%

-2.4%

   

4,770

 

3,121

52.8%

54.5%

-1.7%

SPECIALTY SURGERY

                             

US

 

331

 

336

-1.5%

-1.5%

-

   

650

 

663

-2.0%

-2.0%

-

Intl

 

325

 

310

4.8%

7.5%

-2.7%

   

633

 

611

3.6%

6.2%

-2.6%

WW

 

656

 

646

1.5%

2.8%

-1.3%

   

1,283

 

1,274

0.7%

1.9%

-1.2%

SURGICAL CARE

                             

US

 

577

 

602

-4.2%

-4.2%

-

   

1,108

 

1,195

-7.3%

-7.3%

-

Intl

 

1,011

 

1,038

-2.6%

0.6%

-3.2%

   

1,988

 

2,070

-4.0%

-1.0%

-3.0%

WW

 

1,588

 

1,640

-3.2%

-1.2%

-2.0%

   

3,096

 

3,265

-5.2%

-3.3%

-1.9%

VISION CARE

                             

US

 

262

 

253

3.6%

3.6%

-

   

543

 

530

2.5%

2.5%

-

Intl

 

468

 

477

-1.9%

6.4%

-8.3%

   

927

 

957

-3.1%

4.1%

-7.2%

WW

 

730

 

730

0.0%

5.4%

-5.4%

   

1,470

 

1,487

-1.1%

3.5%

-4.6%

                               

TOTAL MEDICAL DEVICES AND DIAGNOSTICS

                             

US

 

3,243

 

2,953

9.8%

9.8%

-

   

6,449

 

5,830

10.6%

10.6%

-

Intl

 

3,951

 

3,612

9.4%

13.7%

-4.3%

   

7,807

 

7,146

9.2%

12.9%

-3.7%

WW

 

$ 7,194

 

6,565

9.6%

12.0%

-2.4%

   

$ 14,256

 

12,976

9.9%

12.0%

-2.1%

                               

 

* Percentage greater than 100%
(1) Operational growth excludes the effect of currency
(2) Select areas (unaudited)
(3) Nutritionals now reflected in Wound Care/Other, previously reported in OTC/Nutritionals
(4) Prior year amounts have been reclassified to conform to current year product disclosure
(5) Reported as U.S. sales

SOURCE Johnson & Johnson



News Provided by Acquire Media


Close window | Back to top

Copyright 2014 Johnson & Johnson

This site is governed solely by applicable U.S laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy.Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson.Contact Us with any questions or search this site for more information.